Vials and packaging for Eisai's medication Leqembi. Alzheimer’s disease treatment lecanemab is sold under the brand name Leqembi.
A new treatment for Alzheimer’s disease, lecanemab, will likely receive traditional Food and Drug Administration approval on Thursday, marking a tremendous milestone for patients and their families. Unfortunately, the Centers for Medicare & Medicaid Services is closing the door to ready access of this new treatment.As a young physician in training, I became focused on the search for Alzheimer’s treatments because the disease was, and remains, America’s largest single unmet medical need. Alzheimer’s is a tragic dehumanizing illness, resulting in death by inches. When I graduated from medical school, new transgenic mouse models of the disease were being developed.
. Yet now, in what should be a breakthrough moment for our patients and families, CMS is operating with a different set of rules.Last year, the agency denied coverage of anti-amyloid antibodies for Alzheimer’s outside of a new trial. And now, on the precipice of traditional FDA approval for the most effective treatment to date, Medicare will cover it only in select clinical trials with a patient registry, mandating the collection of additional data and study.
Source: Healthcare Press (healthcarepress.net)
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: IntEngineering - 🏆 287. / 63 Read more »
New Bill Would Require Medicare to Cover 'Home Resiliency' Amid Worsening Climate Crisis“Climate justice is a matter of disability justice,' said Sen. Ed Markey. 'It's time that we guarantee that seniors and people with disabilities can safely weather the climate crisis.'
Source: commondreams - 🏆 530. / 51 Read more »
Source: abc15 - 🏆 263. / 63 Read more »
Source: Forbes - 🏆 394. / 53 Read more »
Source: ABC7Chicago - 🏆 284. / 63 Read more »
Source: ForbesTech - 🏆 318. / 59 Read more »